Sky Quarry Inc. (SKYQ): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Sky Quarry Inc. (NASDAQ:SKYQ) said it is advancing a proposed Nevada oil exploration and production initiative targeting up to $50 million in third-party investment in qualified Nevada producers. The structure would invest directly in producers rather than issuing new SKYQ common equity, with potential long-term crude offtake for its Nevada refinery.

Less than 1 min read Sky completed at-the-market sales of approximately 4,408,137 shares, raising about $13,528,940 in net proceeds. Key Highlights: Sold full aggregate amount available under April 22, 2026 prospectus supplement through its ATM program. Issued ~4,408,137 shares (post 1-for-8 reverse split adjustment), generating ~ $13.53M net proceeds. Cantor executed ~52,485 shares for ~ $1.31M; Siebert executed 4,355,652 shares for ~ $12.22M.

Sky Quarry Inc. (NASDAQ: SKYQ) said its Foreland Refinery near Ely, Nevada entered its production phase. The company reported about 10,000 barrels of crude and in-process inventory on site and over 100,000 barrels of storage capacity. It also plans to catalyze drilling in Railroad Valley to supply the refinery and appointed Ray Hansen to run its subsidiary.

Sky Quarry Inc. (NASDAQ: SKYQ) said it signed a non-binding three-year MOU on May 7, 2026 with Southern Energy Renewables and DevvStream to collaborate on SAF and low-carbon fuel development, including pilot testing at its PR Spring oil sands asset in Utah (about 180 million barrels) and upgrades at its Foreland Refinery in Nevada. The Foreland refinery has 5,000 bpd permitted capacity. Sky Quarry also issued RFPs on April 29/May 4 to develop the PR Spring resource and monetize 7 MW of surplus g

BW LPG (NYSE:BWLP) issued $300M in convertible bonds to fund 8 new vessels. The company reported strong Q2 2026 earnings ($120M profit, $0.79 EPS) and high shipping rates. Management expects continued profitability but warns of potential market risks. The bonds may dilute shares if converted, and the company's trading arm shows volatility.

Johnson & Johnson (JNJ) extended its 64-year dividend growth streak with a 3.1% quarterly raise, supported by projected $21 billion in free cash flow. The company's oncology drugs, like CARVYKTI and TREMFYA, offset losses from Stelara biosimilars. JNJ's dividend yield is 1.94%, and shares are up 31.11% year-to-date. The company aims for a 65th consecutive hike in 2027, subject to free cash flow and litigation risks.